The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU, and vincristine chemotherapy
Abstract
OBJECTIVES: To determine the response rate and factors correlated with response of oligodendroglial tumors to procarbazine, lomustine (CCNU), and vincristine (PCV) chemotherapy. DESIGN: Retrospective, observational multicenter study. METHODS: Patients treated with PCV or intensified PCV chemotherapy for a recurrent oligodendroglial tumor after surgery and radiation therapy with measurable disease were retrospectively evaluated for response. A 50% reduction in cross-sectional enhancing tumor area was considered a partial response. Stabilized or responding patients received six cycles of PCV unless unacceptable toxicity occurred. RESULTS: Fifty-two patients were included; median time to progression (MTP) for the entire group was 10 months. In 17% of patients a complete response (MTP, 25 months) was obtained, and in 46% a partial response (MTP, 12 months) was obtained. Median overall survival was 20 months. Although treatment was discontinued for toxicity in seven patients, it was generally well tolerated. The intensified PCV regimen was more toxic. Patients initially presenting with seizures and patients with tumor necrosis in histologic specimens had a better response rate in contrast to patients who had their first relapse within 1 year of first treatment (surgery and radiation therapy). CONCLUSIONS: Oligodendroglial tumors are chemosensitive, but most patients will have relapsed after 12 to 16 months. New studies must aim at improving initial treatment and second-line chemotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An introduction to the free radical hypothesis in Parkinson's disease
Olanow, C. W. (1992) · Annals of Neurology · doi:10.1002/ana.410320703 · Cited by 382
Cited by
van den Bent, M. J., Brandes, A. A., Taphoorn, M. J. B., Kros, J. M., Kouwenhoven, M. C. M., Delattre, J.-Y., Bernsen, H. J. J. A., Frenay, M., Tijssen, C. C., Grisold, W., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.2229 · Cited by 1,226
Self-citationPrimary brain tumours in adults
Ricard, D., Idbaih, A., Ducray, F., Lahutte, M., Hoang-Xuan, K., & Delattre, J.-Y. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61346-9 · Cited by 1,201
Cairncross, G., Wang, M., Shaw, E., Jenkins, R., Brachman, D., Buckner, J., Fink, K., Souhami, L., Laperriere, N., Curran, W., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.2674 · Cited by 1,156
Cognitive deficits in adult patients with brain tumours
Taphoorn, M. J., & Klein, M. (2004) · The Lancet Neurology · doi:10.1016/s1474-4422(04)00680-5 · Cited by 756
Self-citationPrimary brain tumours in adults
Behin, A., Hoang-Xuan, K., Carpentier, A. F., & Delattre, J.-Y. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12328-8 · Cited by 754
Metadata
- Authors
- van den Bent, M. J., Kros, J. M., Heimans, J. J., Pronk, L. C., van Groeningen, C. J., Krouwer, H. G. J., Taphoorn, M. J. B., Zonnenberg, B. A., Tijssen, C. C., Twijnstra, A., Punt, C. J. A., Boogerd, W., & The Dutch Neuro-oncology Group
- Venue
- Neurology
- Published
- 1998-10
- Volume
- 51
- Issue
- 4
- Pages
- 1140-1145
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2131518655
- Cited by
- 206
- References
- 1
- FWCI
- 3.60
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU, and vincristine chemotherapy. https://app.cochat.ai/papers/10.1212/wnl.51.4.1140
- The paper
- van den Bent, M. J., Kros, J. M., Heimans, J. J., Pronk, L. C., van Groeningen, C. J., Krouwer, H. G. J., Taphoorn, M. J. B., Zonnenberg, B. A., Tijssen, C. C., Twijnstra, A., Punt, C. J. A., Boogerd, W., & The Dutch Neuro-oncology Group. (1998). Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU, and vincristine chemotherapy. Neurology. https://doi.org/10.1212/wnl.51.4.1140
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.